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Key Points: 
 
• Mitral valve and left ventricular function are interdependent on each 
other. 
• In mitral regurgitation (MR), measured LV ejection fractions are falsely 
high. 
• Vasopressors should be used with caution in patients with severe MR. 
• New minimally invasive and percutaneous techniques are now available 
to repair the mitral valve.  
• Vasodilating drugs should be used with caution in mitral stenosis (MS). 
 
 
 
The Mitral Valve: 
The mitral valve separates the left atrium from the left ventricle and as such, is 
an integral part of the high pressure systemic circulation. Therefore, any 
pathology of the valve can have critical physiological effects that the anaesthetist 
must be aware of. Anaesthesia alters the way in which the heart, valve and 
circulation interact and control of these changes needs to be both understood 
and anticipated.  
 
Anatomy (see Fig 1): 
The mitral valve is a complex structure that incorporates not only the two main 
leaflets, but an annulus, tendinous cords, and papillary muscles connecting the 
valve leaflets to the left ventricle. 
 
Annulus: 
The mitral valve’s annulus is a saddle-shaped structure which is shaped more 
like a ‘D’ than an ‘O’. The aortic valve is wedged into the straight side of the ‘D’ 
and there is a fibrous continuity between the two valves. This means that one 
can be easily affected by surgery on the other.  
 
The circumflex artery follows the line of the annulus as it passes anteriorly 
around the base of the heart, a position that places it at risk during any mitral 
valve surgery. Damage or ligation of the artery will result in lateral wall 
ischaemia, and this is an important area to assess on peri-operative 
echocardiography. 
 
Leaflets: 
The anterior leaflet hangs down from the straight side of the ‘D’ shaped annulus 
and is more superior and medial than truly anterior. The posterior leaflet is a C-
shaped leaflet divided into three sections by indentations that give it a scalloped 
appearance. These 3 segments are called P1, P2, and P3, with their opposing 
anterior leaflet segments termed A1, A2, and A3. The free edges of the leaflets do 
not meet exactly, but instead have around 5mm of overlap. This overlap at the 
edges seals the valve as the body of the leaflets push outwards like sails during 
systole (see video 1). At the corners of the leaflets there are two commissures 
which ensure a seal in the corners of the valve.  
 
Papillary muscles and chordae: 
During systole the leaflets are prevented from billowing back into the left atrium 
by the chordae. These tether the free edges of the leaflets to the two papillary 
muscles which grow out from the wall of the left ventricle. The papillary muscles 
are antero-lateral and postero-medial and sit under the commissures of the 
valve, with each muscle passing chordae to both leaflets. While the anterolateral 
muscle receives a dual blood supply from the left anterior descending and the 
circumflex artery, the posteromedial is supplied solely by the right coronary 
artery in the more common right dominant circulation. As it is usually only 
supplied by a single artery, infarction and rupture of the posteromedial muscle is 
much more likely, as could be seen in the context of an inferior myocardial 
infarction. 
 
 
Mitral Stenosis: 
A normal mitral valve will have an area of >4cm2 but symptoms are usually only 
present once the stenosis is moderate-severe. Grading into mild, moderate, or 
severe disease is based on both the pressure needed to drive blood across the 
valve (mean pressure gradient) and the valve area. 
 
Aetiology/Epidemiology 
Rheumatic fever is by far the largest cause of mitral stenosis (MS), though it is 
relatively rare in developed countries where degenerative calcification or 
endocarditis are more likely causes. Disease progression is usually around 0.1-
0.3cm2 per year1 but this is greatly increased in cases of repeated valve 
inflammation such as may occur with recurrent bouts of rheumatic fever. This is 
one reason why rheumatic heart disease follows a more indolent course when 
contracted in developed countries where the disease is less common. The 
inflammation results in a thickened, nodular valve that can become fused at the 
leaflet edges and into the commisural edges (see video 2). The chordae can also 
become shortened or thickened, and because blood flows around these cords on 
entering the left ventricle this can cause a sub-valvular obstruction to flow. 
 
Other causes are much less common. These include infiltrating diseases, and 
congenital deformities or diseases that affect multiple systems, such as 
sarcoidosis. 
 
 
 
Signs/Symptoms  
MS is generally well tolerated, and patients will remain asymptomatic for many 
years. This compensation is due to the compliant left atrium dilating and keeping 
pulmonary venous pressures stable. As the disease progresses this 
compensation is gradually overcome and pulmonary hypertension starts to 
develop. Pulmonary oedema and dyspnoea worsen, and patients will complain of 
fatigue and more frequent lower respiratory tract infections. Subtle signs are 
often further delayed by a reduction in activity and may need to be carefully 
sought. Pregnancy and the development of atrial fibrillation will lead to a rapid 
progression of the pathophysiology, and development of symptoms. In 
pregnancy any compensation is overcome by the large increase in blood volume, 
as discussed later.  
 
Classification (see table 1): 
MS is classified on the basis of valve area and pressure gradients across the 
valve. Pressure gradients are relatively simple to assess using echocardiography, 
with a mean pressure >5mmHg indicating moderate stenosis, and >10mmHg 
indicating severe stenosis. Valve area is usually derived using several techniques 
as simply tracing the area out using the echo software can be unreliable. While a 
normal mitral valve has an area of 4-6cm2, symptoms may only develop once the 
valve area is <2.0cm2, with <1cm2 indicating severe disease. 
 
 
 
 
Treatment of Mitral Stenosis: Medical 
Atrial fibrillation: 
In severe MS, up to 40% of patients will develop atrial fibrillation2. An increased 
ventricular response rate decreases diastolic time and increases atrial pressure, 
further worsening symptoms. Rate control reduces symptoms and is generally 
easier to achieve than rhythm control in a heart with dilated atria and fibrosis 
from previous inflammation. It can be achieved with either beta-blockers or 
calcium channel blockers3.  
Dyspnoea: 
Dyspnoea is a common presenting complaint with symptomatic MS. Diuretics are 
used to reduce this, and long-acting nitrates can also provide some relief of 
symptoms. 
Anticoagulation: 
While there is little evidence to justify anticoagulation in MS alone, patients with 
atrial fibrillation, prior embolic events or with a demonstrated left atrial 
thrombus should be anti-coagulated with warfarin (target INR 2-3) or heparin3 4 
 
Treatment of Mitral Stenosis: Surgical 
Surgical options, either open or percutaneous, are the treatment of choice in 
severe symptomatic MS.  In patients with valves with mobile leaflets that are free 
of calcium; percutaneous mitral commissurotomy (PMC) is the preferred option. 
This is performed by passing a balloon across the valve and inflating it, thereby 
splitting the fused commissural edges. PMC achieves an MV area >1.5cm2 with no 
worse than moderate mitral regurgitation in 80% of cases with emergency 
surgery rates of <1%. Surgery is recommended in the presence of atrial 
thrombus, heavy valve calcification or when another open cardiac procedure 
needs to be performed.  Mitral valve replacement is now the preferred treatment 
due to improved valve and clinical outcomes. Mitral valve replacement has an 
operative mortality of 3-5%, but long-term outcomes are highly variable and 
related to multiple patient-related factors (for example, bi-ventricular function, 
pulmonary pressures and atrial fibrillation). 
 
Anaesthetic Management of Mitral Stenosis in non-cardiac surgery 
Preoperative Assessment: 
As mentioned earlier, MS is generally well tolerated and insidious signs need to 
be carefully sought. Symptoms of dyspnoea, fatigue, and a history of frequent 
lower respiratory tract symptoms are suggestive. The indicative low rumbling 
diastolic murmur is best heard in expiration at the apex, with the bell of the 
stethoscope. 
Ongoing elevated PA pressures put strain on the right ventricle, and will 
eventually cause this to fail. Signs of right heart failure, such as a raised JVP and 
peripheral oedema, should be sought on examination. 
As the left atrium dilates, atrial fibrillation is common. Those patients on 
warfarin may need to be converted to heparin preoperatively, depending on a 
number of factors – although if the warfarin is for atrial fibrillation alone, a short 
period with no anti-coagulation carries minimal risk. 
 
 
 
 
Investigations: 
Exercise tolerance testing:  
This provides an objective measure that may unmask poor functional ability in 
patients who have decreased their activity with the onset of symptoms. 
Echocardiography:  
As well as providing information on the severity of the lesion, echo may give 
information on any developing pulmonary hypertension and right heart 
dysfunction. In general, the left ventricle continues to function well.  
In asymptomatic patients, where the systolic pulmonary artery pressure is less 
than 50mmHg, non-cardiac surgery is considered safe5. 
ECG: 
Atrial fibrillation is common, though p-mitrale may be noted if still in sinus 
rhythm 
 
Perioperative management: 
Like aortic stenosis, MS represents a fixed cardiac output state.  
Rate/rhythm:  
If possible, sinus rhythm should be maintained, and a low normal heart rate 
(<70/min) is critical regardless of the rhythm to allow sufficient diastolic time 
for ventricular filling.  
Preload:  
Aim for normovolaemia, keeping in mind that fluid boluses can worsen 
pulmonary oedema.  
Afterload:  
Because the cardiac output is fixed, any reduction in systemic vascular resistance 
can cause a fall in coronary perfusion pressures. Afterload maintenance is 
therefore crucial. Pulmonary vascular pressures should be optimised by avoiding 
hypoxia, hypercapnia and acidosis to prevent acute right ventricular 
decompensation. Nitrous oxide should not be used as it can cause further rises in 
pulmonary vascular resistance in those patients where it is already elevated. 
Contractility:  
The left ventricle will usually be unaffected. The right ventricle may need 
support if signs of failure are present. After ensuring pulmonary vascular 
resistance is as low as possible, inotropes such as phosphodiesterase inhibitors 
or catecholamine agonists may be required to augment the right ventricular 
contractility. Care should be taken with phosphodiesterase inhibitors due to 
their vasodilating effects on the systemic system resulting in afterload reduction 
and hypotension. 
 
Neuraxial Anaesthesia: 
Neuraxial anaesthesia causes a drop in afterload, and so has the potential for 
profound hypotension in MS. This may lead to a spiral of poor myocardial 
perfusion and worsening cardiac function. As such, the decision to undertake 
neuraxial anaesthesia in MS should not be made lightly. Consideration should 
also be given to the fact that the patient may be anticoagulated. 
 
Postoperative Management: 
Care needs to be taken to observe the same fundamentals of management in the 
post-operative period. This is generally best achieved in a high-dependency unit 
unless surgery is extremely minor. Instructions to avoid fluid boluses should be 
given to the recovery staff, and any hypotension should mandate Anaesthetic 
review and aggressive treatment. 
Post cardiac surgery:  
After repair or replacement, preload should be well maintained, and afterload 
reduced to promote forward flow. The right heart may still need support in the 
form of pulmonary vascular resistance reduction and inotrope infusion. Surgical 
alterations to the mitral annulus can affect how the left heart contracts. This, 
combined with the effects of open heart surgery and cross-clamping with 
cardioplegia, mean that the left heart is also at risk of failure during this period.  
 
Management of Mitral Stenosis in pregnancy: 
Due to the increase in blood volume and heart rate in pregnancy MS is poorly 
tolerated, and frequently will first present at this time. In normal pregnancy 
cardiac output increases ~50%, though the fixed cardiac output state of MS 
results in a worsening of pressure through the pulmonary circulation and into 
the right heart. The risk of decompensation depends on severity. Anything worse 
than moderate disease (valve area <1.5cm2) frequently results in heart failure, 
which usually develops in the second or third trimester and is progressive6  
Medical management through pregnancy involves aggressive control of 
tachycardia and atrial fibrillation, with beta-blockers the mainstay of treatment. 
Diuretics are also added if symptoms of pulmonary congestion develop. If 
symptoms are not controlled with medical therapy, percutaneous 
commisurotomy is the surgical treatment of choice as it avoids bypass with the 
attendant risk to the fetus. 
 Delivery: 
Haemodynamic goals for delivery remain afterload maintainence, heart rate and 
rhythm control, and care with fluid administration. Vaginal delivery is well 
described, but is carefully managed. Neuraxial analgesia is placed early to block 
any tachycardia due to sympathetic stimulation. Blockade is achieved slowly and 
any hypotension is managed with alpha-agonists. Epidurals are titratable, with a 
mixture utilising opioids achieving analgesia with fewer haemodynamic effects. 
The second stage is assisted, limiting labour duration and valsalva. In patients 
with pulmonary hypertension, or NYHA III/IV symptoms despite maximal 
medical therapy, caesarean section is considered.  
 
Post-delivery, patients with MS are at risk of developing pulmonary oedema. 
This can occur precipitously as a result of decompression of the IVC along with 
autotransfusion due to uterine compression causing a sudden increase in 
preload. This ‘flash’ pulmonary oedema can be initially managed with head-up 
positioning, and the institution of 100% oxygen. This may necessitate intubation 
and ventilation if severe, with sufficient positive end-expiratory pressure (PEEP). 
Also of note, oxytocin should be administered with great care in the MS 
population due to its vasodilating properties on the systemic circulation and 
propensity to increase pulmonary vascular resistance. Ergometrine is 
contraindicated due to its pulmonary vasoconstricting effects. 
 
 
 
Mitral Regurgitation: 
Mitral regurgitation (MR) can be acute or chronic in onset, and primary or 
secondary in nature. Primary MR is due to pathology of the valve preventing 
normal closure, whereas secondary MR is caused by left ventricular dysfunction 
that affects the closing of the mitral valve (this is also known as “functional” MR). 
In either case, the left atrium dilates as blood is ejected back into it. This dilation 
can be significant, and atrial fibrillation is common. Overload of the pulmonary 
circulation causes dyspnoea, although frank pulmonary oedema is usually only 
seen in acute MR and in severe chronic disease. The left ventricle is volume 
overloaded in MR, with dilation of the ventricle further worsening MR through 
annular dilatation. 
 
Acute Mitral Regurgitation 
Acute MR can be caused by any disruption to the normal mechanism of the valve. 
Examples of pathology include the growth of vegetations on the leaflets in 
infective endocarditis, chordae rupture in patients with pre-existing 
degenerative disease, or papillary muscle rupture due a ST-elevation MI (usually 
affecting the inferior territory).  
The left atrium is unable to compensate acutely for the increased pressure 
caused by blood refluxing back into it. As the pressure is transmitted back into 
the pulmonary circulation, patients can present with sudden onset dyspnoea and 
require rapid stabilisation and treatment. 
 
 
 
Chronic Mitral Regurgitation 
In chronic primary disease there is an abnormality of the leaflets that prevents 
them from closing normally. The major cause for this is degenerative disease 
resulting in leaflet prolapse (see video 3). 
 
Chronic secondary MR is also known as functional MR because the anatomy of 
the valve is normal, but its function is impaired due to left ventricular pathology. 
This may be as a result of dilation of the mitral annulus with left ventricular 
dilatation such that the leaflets can’t meet adequately, or due to abnormal 
movement (dyskinesia) of the left ventricle following ischaemia or infarction. 
Systolic anterior motion (SAM) of the anterior mitral leaflet into the left 
ventricular outflow tract can occur in conditions such as hypertrophic 
cardiomyopathy, especially when hypovolaemic. This results in obstruction to 
outflow into the aorta, and also simultaneous regurgitation across the distorted 
mitral valve. 
 
Classification (see table 2): 
Grading the severity of the MR is complex and involves several techniques. 
Tranoesophageal echocardiography (TOE) remains the gold standard for 
defining the severity of the MR, though transthoracic echocardiography is 
sufficient if good images are acquired. Determination of the severity is made 
using several measurements including effective regurgitant orifice area (EROA), 
regurgitant volume, and regurgitant fraction. These are correlated with other 
measurements, such as the narrowest part of the regurgitant jet (vena contracta) 
to support the diagnosis. 
 Treatment of Mitral Regurgitation: Medical 
In acute MR the goals include filling pressure reduction with nitrates or diuretics, 
and afterload reduction with vasodilators or an intra-aortic balloon pump (IABP) 
as bridging to definitive treatment. 
 
Vasodilator use promotes forward flow into the aorta and so reduces the 
regurgitant fraction, however their use can be limited by hypotension. In this 
case inotropic agents or an IABP should be added. The IABP decreases afterload 
by deflating during systole (reducing afterload and therefore reducing the work 
of the heart). The inflation of the balloon during diastole increases the pressure 
in the aortic root which in turn increases coronary perfusion pressure. 
 
In chronic MR with signs of heart failure, the treatment is in line with standard 
heart failure management including beta-blockers, ACE inhibitors and 
aldosterone antagonists, with diuretics used where heart failure is present. In 
addition, if cardioversion is attainable it will often immediately reduce MR 
severity. However, there is no proven benefit to any medical therapy for MR 
without left ventricular dysfunction, and generally when such dysfunction does 
develop it is an indication for surgery.  
 
Treatment of Mitral Regurgitation: Surgical 
The decision on when to operate can be complex.3 It depends not only on 
whether the MR is primary or secondary in nature, but also on the condition of 
the patient, their response to therapy and the development of sequelae such as 
heart failure or atrial fibrillation. 
 
Primary MR: 
In primary MR the evidence to operate is clear: surgery is indicated if the MR is 
severe and acute in nature, such as from a ruptured papillary muscle. If the MR is 
chronic and causing symptoms, and there are no contraindications to surgery, 
repair is also clearly indicated. 
However, if the patient is asymptomatic then clear consequences from the MR 
have to be seen, whether this be an LVEF <60% or the development of AF or 
pulmonary hypertension. Surgery is generally avoided if the heart failure is 
severe (LVEF <30%). 
 
Secondary MR: 
The indications for surgical treatment of secondary MR is less evidence-based 
than with primary MR.  
In patients already undergoing CABG it appears clear that repair of severe MR is 
indicated. However, whether to repair moderate MR or not during CABG is less 
obvious. 
In symptomatic patients, with severe LV failure the benefits of surgery are felt to 
be questionable unless there is some reversibility of the underlying problem, 
such as revascularisation of viable myocardium. 
Surgery is also considered in symptomatic patients with moderate LV failure if 
medical therapy has failed. 
With regards to to the type of surgery, valve repair, rather than replacement, is 
invariably preferred for primary MR if at all possible. Repair has significantly 
reduced operative mortality3 and better preservation of LV function when 
compared to replacement and avoids the long-term consequences of prosthetic 
valves.  
 
For secondary disease, such as ischaemic MR, repair results in reduced early 
mortality but a higher degree of recurrent MR in the long-term. Otherwise, the 
long-term outcomes of repair versus replacement for ischaemic MR are similar7.  
 
Minimally invasive surgery 
Mitral valve repair and replacement can also be performed through a small right 
thoracotomy and several small instrument ports with a femoral incision for 
bypass cannula insertion. Standard operative techniques are used under 
endoscopic view. The safety and efficacy of this approach has been well 
demonstrated and is similar to the traditional midline sternotomy approach in 
the hands of experienced surgeons. 
Robotic telemanipulators are developing a place in mitral valve surgery since 
their first use in 1998. Their dexterity helps the surgeon place sutures in difficult 
to reach positions more precisely. While bypass and cross-clamp times are 
longer, times to discharge and return to work are shorter8. Robotic arms can be 
used in all types of mitral surgery, although long-term outcome data is awaited. 
 
Percutaneous mitral valve repair: 
Recent trials have shown efficacy of the Mitraclip system for percutaneous 
repair in moderate-severe or severe MR9 in patients deemed too high risk for 
surgery. This technique works by clipping the two leading edges of the leaflets 
together and creating a double orifice into the left ventricle (see Fig 2). The 
Mitraclip system is less effective at reducing MR in the short-term but has 
similar outcomes at 12 months. It results in improved LVEF, NYHA score and 
quality of life compared to baseline. Although in the randomised EVEREST trial, 
20% of the patients required further surgical intervention, the role of the 
Mitraclip system is expanding in high-risk surgical patients. 
 
Anaesthetic Management of Mitral Regurgitation in non-cardiac surgery 
Preoperative Assessment: 
While acute MR can present as florid cardiac failure with severe pulmonary 
oedema, chronic MR can be tolerated for many years, with symptoms only 
developing as the left ventricle starts to fail.  
As with MS, signs of pulmonary hypertension and right heart failure should be 
sought as the increased pressure is transmitted back through the pulmonary 
circulation to the right heart.  These signs include dyspnoea, fatigue and frequent 
chest infections indicating pulmonary hypertension, or peripheral oedema and a 
raised JVP to indicate right heart failure.  
The pansystolic murmur of MR is frequently very soft, and its intensity is 
unrelated to the severity of the disease. There may be a displaced and forceful 
apex beat palpable. 
 
 
Investigations:  
Echocardiography:  
Echo is useful when grading the severity of the lesion. However, the left 
ventricular function is more difficult to assess. As blood is being ejected in 
systole through both the aortic and regurgitant mitral valves, the ejection 
fraction appears to be higher than normal. Therefore, a left ventricle ejection 
fraction of around 70% is thought to be normal in MR (cf. 55% ‘normally’), with 
levels below 60% representing left ventricular dysfunction. 
ECG:  
Signs of ischaemia should be sought, especially in functional MR. If the patient 
presents with acute or new-onset MR this may be due to recent papillary muscle 
rupture. History of the event may be vague and ECG may aid the diagnosis. As an 
inferior myocardial infarction is the most likely cause of papillary muscle 
rupture, ST changes in leads II, III and aVF may suggest the diagnosis.  
Blood tests:  
Brain Natriuretic Peptide (BNP) can be useful in prognostication, with low 
plasma BNP having a high negative predictive value for developing further 
complications10. 
Exercise testing:  
Symptoms of chronic MR can often be masked by the patient simply reducing 
their exertion to a level they are capable of. Formal testing, such as 
cardiopulmonary exercise testing, is of clear utility if the echo findings don’t 
match with the symptom history, and may give a clearer picture of ventricular 
function. 
 
If LV function is preserved and the patient is asymptomatic then non-cardiac 
surgery can be performed with no additional risk, even if the MR is severe11. In 
fact, the risk associated with non-cardiac surgery rises only when the left 
ventricle function is severely impaired (<30%) or the patient is symptomatic. In 
these cases medical optimisation must be assured before proceeding. 
 
Perioperative management: 
As with all regurgitant lesions, the haemodynamic goals can be summarised as 
“full, fast and forward flow”. 
Rate/rhythm:  
A high normal heart rate (80-100bpm) reduces filling time of the left ventricle. 
This helps counteract overload of the ventricle and encourages forward flow. 
The desire for an elevated heart rate needs to be balanced with myocardial 
oxygen demand and supply considerations in the presence of ischaemic heart 
disease. 
Preload:  
Assessment of preload can be difficult in MR. Erring on the side of well-filled is 
preferable as it also promotes forward flow. 
Afterload:  
As systemic vascular resistance rises, so does the regurgitant fraction. Falls in 
blood pressure should be treated with fluid and elevating the heart rate -  
vasoconstrictors can be used with care. Pulmonary vascular resistance should be 
kept as low as possible by strict avoidance of hypoxia, hypercapnia and acidosis 
and avoiding the use of nitrous oxide. 
Contractility:  
In acute MR, inotropes such as dobutamine or even inodilators such as 
enoximone or levosimendan may be needed - especially if there is evidence of 
left ventricular failure. In this case, consideration should be given to the insertion 
of an IABP pre-operatively.  
 
Neuraxial Anaesthesia: 
Neuraxial anaesthesia is generally well tolerated with MR as the afterload is 
reduced, which aids forward flow.  Vasopressors need to be titrated with care. 
 
Postoperative Management: 
Recovery staff should be made aware of the cardiac diagnosis, and the same peri-
operative principles should be adhered to. 
Post cardiac surgery: 
After replacement of the valve, there is no low-pressure system for the left 
ventricle to eject into and it will suddenly be subjected to a higher workload. 
Poor function may be unmasked, and inotropes and inodilators should be 
considered. Systemic vascular resistance should be minimised if possible to 
allow forward flow and to ‘offload’ the ventricle. If an IABP was needed pre-
operatively this is generally left in place post-operatively until haemodynamic 
and metabolic stability have been achieved.  
 
Management of Mitral Regurgitation in pregnancy: 
Pregnancy mimics the haemodynamic goals for regurgitant lesions with an 
increase in heart rate and blood volume, and a fall in systemic vascular 
resistance promoting forward flow. Because of this, pregnancy is generally well 
tolerated, even if MR is severe, as long as left ventricular function is preserved3. 
Patients whose left ventricular function is impaired, or have severe symptomatic 
MR, are at increased risk of heart failure. Diuresis is commonly used to limit fluid 
overload, and this is usually all the medical therapy that is needed.  
Delivery: 
Vaginal delivery is generally possible with epidural anaesthesia and an assisted 
second stage to avoid spikes in the systemic vascular resistance seen with 
pushing. 
 
Summary: 
Anaesthetists are an integral part of any team undertaking surgical management 
of a patient with mitral valve disease. An understanding of the pathophysiology 
allows the anaesthetist to not only engage in decisions regarding treatment, but 
to anticipate and manage the consequences of surgery and anaesthesia.  
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Figures and Tables 
Mitral Stenosis 
 
 
 
 
Mild Moderate Severe 
Mean Pressure Drop <5mmHg 6 – 10mmHg >10mmHg 
Pressure Half Time <139ms 140 – 219ms ≥220ms 
Valve Area 1.6 - 2.0cm2 1.5 – 1.0cm2 <1.0cm2 
 
Table 1. Criteria for echocardiographic diagnosis of mitral stenosis severity12 
Mitral Regurgitation    
 Mild Moderate Severe 
Regurgitant Fraction <30% 30-49 ≥50% 
Regurgitant Orifice Area <0.20cm2 0.2 – 0.39 cm2 ≥0.40cm2 
Regurgitant Volume <30ml/beat 30 - 59ml/beat ≥60ml/beat 
 
Table 2. Criteria for echocardiographic diagnosis of mitral regurgitation 
severity12. 
 
 
 
  
Figure 1. The mitral valve and surrounding structures. The valve is in the 
‘surgeon’s view’ orientation with the heart tilted to the left. (Panel A): AC - 
Anterior commissure. PC - posterior commissure. Panel B shows the mitral-valve 
leaflets, each of which usually consists of three discrete segments or scallops. 
These are designated A1, A2, and A3 for the anterior leaflet and P1, P2, and P3 
for the posterior leaflet. Panel C - Primary chordae are attached to the free edge 
of the valve leaflet, and secondary chordae are attached to the ventricular 
surface of the leaflet. (Used with permission from the NEJM)13  
 
 Figure 2: Repair of mitral regurgitation with the Mitraclip system. A dual 
inlet mitral valve results, with reduced regurgitation. In patients with mitral 
regurgitation resulting from incomplete leaflet co-aptation (Panels A and B), 
percutaneous mitral-valve repair is performed by means of femoral venous and 
trans-septal access to the left atrium to steer the device toward the origin of the 
regurgitant jet (Panel C). The Mitraclip is passed through the mitral orifice 
from the left atrium to the left ventricle and pulled back to grasp the leaflet edges 
(Panels D and E). If reduction of the mitral regurgitation is satisfactory, the 
device can be locked and then released (Panel F). A double orifice is created in 
conjunction with reduction in mitral regurgitation (Panels G and H). (Used with 
Permission from the NEJM)9 
 
Video 1. Trans-oesophageal echo of normal mitral valve (mid-oesophageal 5-
chamber view). The left atrium is at the top of the image and the mitral valve is 
seen separating the left atrium from the left ventricle. Part of the aortic valve is 
seen in the centre of the picture. 
 
Video 2. Trans-oesophageal echo of stenotic mitral valve (mid-oesophageal 4-
chamber view). The leaflet tips are thickened and do no open widely. Note the 
dilated left atrium (at the top of the image). 
 
Video 3. Trans-oesophageal echo of posterior mitral valve leaflet prolapse and 
flail (mid-oesophageal 4-chamber view). The posterior mitral valve leaflet rises 
above the mitral valve annulus and results in regurgitation of blood into the left 
atrium. 
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The Mitral Valve and Mitral Valve Disease MCQs 
 
1. A 72 year old man undergoes an elective mitral valve repair involving an 
annuloplasty ring and returns to the ICU. He rapidly becomes hypotensive 
and trans-oesohageal echo reveals a new regional wall motion 
abnormality of the lateral wall. Appropriate statements on this 
complication may include: 
(a) The right coronary artery is at risk in this procedure and has likely 
been damaged. 
(b) Staring a noradrenaline infusion will improve his coronary perfusion 
and resolve the regional wall motion abnormality. 
(c) Papillary muscle rupture is a recognised outcome from this 
complication. 
(d) Medical management is appropriate at this point. 
(e) The circumflex artery may have been damaged or ligated, and this 
patient needs surgical intervention. 
 
  
 
 
1. (a) False The right coronary artery is not near the surgical field, 
and damage is unlikely. The right coronary supplies the 
right ventricle and usually the inferior left ventricular 
wall, not the lateral wall.  
(b) False Starting a noradrenaline infusion may improve this 
patients coronary perfusion pressure. However, the 
cause of the regional wall motion abnormality is likely 
to be mechanical obstruction of his circumflex artery of 
a surgical aetiology. This will not be remedied by 
noradrenaline. 
(c) False Lateral wall ischaemia indicates circumflex artery 
pathology. The anterolateral papillary muscle receives 
dual blood supply from both the circumflex and the left 
anterior descending arteries and so is unlikely to infarct. 
(d) False This patient requires urgent surgical intervention as the 
causative lesion is almost certainly due to a surgical 
complication and could not be appropriately managed 
with medical therapy alone. 
(e) True The circumflex runs very close to the mitral annulus and 
may well have been ligated by a suture (and often even 
closer in those with left dominant systems). A return to 
theatre or catheter lab is indicated as the damage needs 
to be repaired, or the area bypassed with a graft or 
stent. 
  
2. A 54 year old previously fit and well lady presents to Accident and 
Emergency with a vague history of chest pain and worsening shortness of 
breath over the last 3 days. She is noted to have a systolic murmur, which 
the patient denies previous knowledge of. Troponins are elevated. 
Regarding further investigation and treatment for this patient: 
(a) ST elevation in II, III and aVF indicates an inferior myocardial 
infarction with potential for subsequent papillary muscle rupture. 
(b) Her ECG is likely to reveal ST segment changes in V2-V5 
(c) This lesion is likely to be amenable to percutaneous treatment. 
(d) This patient may become shocked and will require cautious 
resuscitation with fluid boluses and potentially inotrope support. 
(e) If hypotension develops, vasopressors should be used to support her 
blood pressure. 
 
  
 
2. (a) True Inferior myocardial infarction is the most likely to result 
in papillary muscle rupture due to the right coronary 
artery providing the sole blood supply to the 
posteromedial papillary muscle. When this occurs it 
results in severe mitral regurgitation. 
(b) False This would indicate an anterior myocardial infarction 
which is very unlikely to result in this pathology due to 
the dual blood supply of the anterolateral papillary 
muscle. Of note, ST segment reciprocal depression may 
be seen in the inferior leads with an anterior myocardial 
infarction. 
(c) False While the coronary artery stenosis may be amenable to 
percutaneous correction this patient requires surgical 
intervention for the ruptured papillary muscle. The 
causative stenosis can be bypassed at this time. 
(d) True As this is acute mitral regurgitation, haemodynamic 
support should include cautious fluid administration 
with inotropes. 
(e) False Vasopressor use alone will increase afterload and 
worsen the backflow from the left ventricle through the 
regurgitant mitral valve. 
  
3. A 74 year old gentleman is seen in pre-assessment clinic for a trans-
urethral prostate resection. Exercise is limited by his knee pain and denies 
orthopnoea, though admits to poor sleep due to bladder symptoms. He 
takes warfarin for atrial fibrillation. You detect a murmur on exam, and 
limited echo reveals severe mitral stenosis. Regarding this patient: 
(a) Spinal anaesthesia would be a reasonable option. 
(b) As this patient is relatively asymptomatic, it is safe to proceed with 
this surgery. 
(c) When he presents for surgery, he will likely require fluid preloading 
prior to induction. 
(d) This patient is high risk, and requires further investigation including 
a stress echocardiogram and assessment of pulmonary artery 
pressures. 
(e) Cardioversion will be required prior to proceeding. 
 
  
 
3. (a) False Mitral stenosis is a fixed output state, and cardiac 
output would not be able to increase in the face of a 
reduction in afterload caused by spinal anaesthesia.   
(b) False Mitral stenosis typically has an insidious symptom 
profile. This patient’s history is not reassuring, and 
further investigation is required. 
(c) False Fluid preloading is not indicated in mitral stenosis. The 
cardiac output cannot increase and so fluid loading will 
cause an increase in pulmonary vascular pressures and 
subsequent oedema. 
(d) True Symptoms of mitral stenosis are often difficult to illicit 
on history. A stress echocardiogram may provide an 
objective measure of functional ability of the heart to 
increase work in the face of increasing demand. 
(e) False Atrial fibrillation is very common in mitral stenosis. 
While rate control is important, cardioversion is 
unlikely to be successful. 
  
4. An active 72 year old lady is placed on the acute theatre list for 
hemiarthoplasty after falling and fracturing her neck of femur while 
ballroom dancing. A systolic murmur is detected during preoperative 
assessment. Echocardiography reveals severe mitral regurgitation with a 
left ventricular ejection fraction of 60% and preserved right ventricular 
function 
(a) Surgery needs to be delayed until a stress echocardiogram can be 
performed. 
(b) Spinal anaesthesia is unsafe in this patient. 
(c) Fluid boluses may be needed prior to induction, or to control 
hypotension. 
(d) Surgery can go ahead without further delay. 
(e) Surgery on the hip needs to be combined with mitral valve repair or 
replacement. 
 
  
 
4. (a) False While stress echocardiography will give a better idea of 
ventricular function. It is not necessary to delay this 
emergency surgery in an asymptomatic patient. 
(b) False Spinal anaesthesia causes a fall in afterload, which is 
beneficial in mitral regurgitation. It is generally well 
tolerated with the usual precautions, and would be a 
reasonable option for this surgery. 
(c) True The haemodynamic goals of mitral regurgitation include 
maintaining adequate preload and an assessment of the 
patient’s fluid status is an important part of the 
preoperative consultation. 
(d) True While this patient likely has borderline mild LV 
impairment with an ejection fraction of 60%, the fact 
she is active and asymptomatic means she is fit for 
surgery.   
(e) False Mitral valve surgery does not need to be undertaken at 
this time. The patient is asymptomatic with a good LV, 
though she will require surveillance as any further fall 
in LV function may be an indication for surgery. This 
should not delay her hip surgery. 
  
5. The obstetric registrar notifies you of a category 2 caesarean section on an 
18 year old primip with an epidural in situ. She is known to have mitral 
stenosis from previous rheumatic fever. The delivery plan is for controlled 
epidural top-up which proceeds uneventfully. Immediately post-delivery 
she complains of difficulty breathing and becomes acutely dyspnoeic. 
Regarding this situation: 
(a) Oxytocin has likely been administered too rapidly and this effect will 
be transient. 
(b) This patient requires immediate intubation and ventilation before 
she deteriorates further. 
(c) A fluid bolus should be one of the first measures to help stabilise the 
patient. 
(d) This patient should be placed head up and given 100% oxygen with 
positive end expiratory pressure. 
(e) This patient is likely to have a high block from the epidural top-up. 
 
  
 
5. (a) False While oxytocin needs to be administered cautiously in 
mitral stenosis, it’s principal effect is vasodilation and 
hypotension which can be profound. 
(b) False This patient may require intubation as part of the 
management of this complication, but more 
conservative measures should be attempted first. 
(c) False This complication is the result of a massive 
autotransfusion overwhelming the ability of the heart to 
increase its cardiac output due to the mitral stenosis. 
Care always needs to be taken with fluid administration 
with any stenotic valve lesion. 
(d) True The release of inferior vena cava compression and 
autotransfusion from uterine contraction have 
combined to significantly increase preload. The 
presentation can be similar to amniotic fluid embolus, 
but given the patient’s history the administration of 
oxygen with PEEP and a head up position should be the 
first line of treatment 
(e) False Epidural top-up needs to be conducted in a slow, steady 
fashion in patients with mitral stenosis. Unless the 
Anaesthetist has been overly enthusiastic with the 
boluses, this is an unlikely scenario. Of note, head up 
positioning will aid regression of the block if it cannot 
be excluded. 
 
 
 
 
 
